港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

靖因藥業（臨時代碼）

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

靖因藥業IPO：32項重大專利未獲授權靠非經常損益扭虧只是曇花一現？

靖因藥業衝擊IPO，聚焦小核酸創新藥領域，尚未有產品獲批

騰訊參股靖因藥業港股IPO：核心產品尚處臨牀階段II期，部分研發依賴合作方

靖因藥業闖關港交所，兩年合計虧損6.5億元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91273"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"91273","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","market":"HK","secType":"STK","nameCN":"靖因藥業（臨時代碼）","latestPrice":0,"timestamp":1770969600000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"02-13 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91273\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91273\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91273\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91273\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583526498","title":"靖因藥業IPO：32項重大專利未獲授權 靠非經常損益扭虧只是曇花一現 ？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526498","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526498?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 13:38","pubTimestamp":1763098680,"startTime":"0","endTime":"0","summary":"　　近日，靖因药业正式向港交所递交了上市申请，高盛、海通国际及汇丰担任联席保荐人。招股书显示，靖因药业成立于2021年，致力于siRNA疗法开发。知识产权方面，多项核心专利悬而未决，技术护城河尚未建成。　　此外，截至最后可行日期，靖因药业拥有65项专利和专利申请，但其中仅有一项“多核苷酸构建体”专利获得授权。包括32项对集团业务而言属重大的专利在全球均处于“待决”状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkanu9175307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91273"],"gpt_icon":0},{"id":"2581001744","title":"靖因藥業衝擊IPO，聚焦小核酸創新藥領域，尚未有產品獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001744","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001744?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 17:19","pubTimestamp":1762334385,"startTime":"0","endTime":"0","summary":"两年半亏损6.16亿元","market":"hk","thumbnail":"https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3137174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","BK1574","06978","91273"],"gpt_icon":0},{"id":"2577371626","title":"騰訊參股靖因藥業港股IPO：核心產品尚處臨牀階段II期，部分研發依賴合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2577371626","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577371626?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 16:54","pubTimestamp":1761209646,"startTime":"0","endTime":"0","summary":"靖因药业致力于siRNA疗法开发，不过目前仍处于临床阶段，尚无营业收入。此后，多款siRNA药物相继成功上市，目前，全球主要市场已有7款siRNA产品获批上市。据招股书，靖因药业的主要产品资产包括SRSD107、SRSD216、SRSD384等。该产品目前正处于欧洲II期多中心临床试验阶段，并计划在中国及澳大利亚/新西兰启动另一项II期试验。未来，靖因药业能否在技术、产品等方面占据长久优势，与CRISPR等伙伴的合作效益有多大，核心产品何时实现商业化突围，都还存在变数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1761209425076239506","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0320764755.SGD","LU1719994722.HKD","LU0441854154.USD","LU0862451753.SGD","LU1048596156.SGD","LU2237443465.HKD","IE0032431581.USD","LU0449509016.USD","LU0634319403.HKD","LU2462611646.USD","LU1282648689.USD","LU0456842615.SGD","HTCD.SI","LU0577902611.USD","LU0823041008.USD","LU1481107354.HKD","LU0823038988.USD","LU1504937902.USD","BK1609","LU0348816934.USD","LU0132412106.USD","LU2778985437.USD","91273","LU1211504680.USD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0675040207.SGD","IE00BQXX3C00.GBP","IE00B5MMRT66.SGD","LU0918141887.USD","LU1008478684.HKD","LU0072913022.USD","IE00B0169N27.USD","LU2045819591.USD","LU0516423091.SGD","LU0823426308.USD","IE0032834883.USD","LU0348827113.USD","LU0588545904.SGD","LU0348735423.USD","LU2106854487.HKD","IE00BGV7N243.SGD","LU0823039010.USD","SGXZ99366536.SGD","TCHmain","BK1610","LU0823426480.USD","LU1974910355.USD"],"gpt_icon":1},{"id":"2573694679","title":"靖因藥業闖關港交所，兩年合計虧損6.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573694679","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573694679?lang=zh_tw&edition=fundamental","pubTime":"2025-10-05 11:53","pubTimestamp":1759636380,"startTime":"0","endTime":"0","summary":"　　港交所官网信息显示，靖因药业9月28日递交招股书，高盛、海通国际、汇丰为联席保荐人。靖因药业于2021年由OrbiMed Entities及 Creacion Ventures联合创立，是一家创新生物技术公司，聚焦新一代核酸创新疗法在心血管疾病领域的开发。靖因药业获此轮融资后估值为2.53亿美元。　　控股股东方面，OrbiMed实体是靖因药业的控股股东。62岁的冀群升持有靖因药业5.87%的股权，并担任公司的执行董事兼首席执行官。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2025-10-05/doc-infsvfqr5327789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HEXmain","91273"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91273\",params:#limit:6,delay:false,,,undefined,":[]}}